6163ÒøºÓ

English

6163ÒøºÓÉúÎïѪ˨ËÄÏî | ΪDICÔçÆÚÕï¶ÏÌṩÓÐÁ¦Ö§³Ö

Ðû²¼ÓÚ£º2024-12-20

ÎÄÕÂȪԴ£º[ÖÐÎÄ]6163ÒøºÓÉúÎï




01

DIC¸ÅÊö


ÃÖÉ¢ÐÔѪ¹ÜÄÚÄýѪ£¨disseminated intravascular coagulation£¬DIC£©ÊÇÔÚÐí¶à¼²²¡»ù´¡ÉÏ£¬Ö²¡ÒòËØËðÉË΢Ѫ¹Üϵͳ£¬µ¼ÖÂÄýѪ»î»¯£¬È«Éí΢Ѫ¹ÜѪ˨Ðγɡ¢ÄýѪÒò×Ó´ó×ÚÏûºÄ²¢¼Ì·¢ÏËÈÜ¿º½ø£¬ÒýÆðÒÔ³öѪ¼°Î¢Ñ­»·Ë¥½ßÎªÌØÕ÷µÄÁÙ´²×ÛºÏÕ÷¡£


DIC²»ÊÇÒ»¸ö×ÔÁ¦µÄ¼²²¡£¬¶øÊÇÖڶ༲²¡ÖØ´ó²¡ÀíÀú³ÌÖеÄÖÐÐÄ»·½Ú£¬Æä»ù´¡¼²²¡»òÓÕÒò°üÀ¨£ºÑÏÖØÑ¬È¾£¨Å§¶¾Ö¢µÈ£©¡¢¶ñÐÔÖ×Áö¡¢²¡Àí²ú¿Æ¡¢Íâ¿ÆÊÖÊõ¼°ÍâÉËÖж¾ºÍÃâÒßËðÉ˵È£¬ÆäÖÐѬȾÊÇ×î³£¼ûµÄÔµ¹ÊÔ­ÓÉ¡£


DIC¼²²¡Ìص㣺Æð²¡ÒþÄ䣬ÔçÆÚ¿ÉÎÞÏÔÖøÌØÕ÷£¬¾ßÓÐÏ£Íû¿ì¡¢Ô¤ºó²î¡¢éæÃüÂʸߵÈ¡£


DICʹ»¼Õ߯÷¹ÙË¥½ßºÍéæÃüµÄΣÏÕÐÔÏÔ×ÅÔöÌí£¬ÔÚ²î±ð±¨µÀÖУ¬DIC»¼Õß²¡ËÀÂʸߴï31%~86%£¬Òò´ËÓÐѧÕß°ÑDICг³ÆÎª¡°Death Is Coming¡±¡£ÓÉÓÚDIC»ù´¡¼²²¡ºÍÁÙ´²ÌåÏÖ¶àÑù»¯¡¢·ÖÆÚÖØ´ó£¬Ê¹ÆäÈÝÒ×ÓëÆäËûÒýÆð³öÄýѪÒì³£¼²²¡Ïà»ìÏý£¬¼«Ò×±»ºöÊÓ£¬ÑÏÖØÓ°Ï컼ÕßÔ¤ºó£¬Òò´ËDICµÄÔçÆÚÕï¶ÏÊÇDICÕïÖεÄÒªº¦¡£





6163ÒøºÓÉúÎïѪ˨ËÄÏîÒÑÈ¡µÃ×¢²áÖ¤£¬ÔÚDICÔçÆÚÕï¶Ï¿ÉÒÔÌṩÓÐÁ¦Ö§³Ö£¡



02

DICÕï¶Ï±ê×¼µÄÏÖ×´


DICµÄ±¬·¢ÆøÖÆÖØ´ó£¬Ö²¡ÒòËØ²î±ð£¬Æä¶ÔÓ¦µÄ²¡ÀíÐÄÀí»úÖÆ¼°ÁÙ´²ÌصãÒ²±£´æºÜ´ó²î±ð£¬DICµÄÕï¶ÏÊÇÏÖÔÚÁÙ´²±£´æµÄÒ»¸öÄÑÌâ¡£



ÏÖÔÚÖ¸ÄÏÍÆ¼öʹÓùú¼ÊѪ˨ÓëֹѪѧ»á±ê×¼£¨ISTH-DIC£©¡¢ÖйúDICÕï¶Ï»ý·Öϵͳ£¨CDSS-DIC£©ÆÀ·ÖϵͳÕï¶ÏDIC¡£±ðµÄ£¬2019ÄêISTH¹«²¼ÁËŧ¶¾Ö¢ÐÔÄýѪ²¡(sepsis-induced coagulopathy£¬SIC)Õï¶Ï±ê×¼£¬ËäÈ»ÏÖ´æÐí¶àDICÕï¶Ï±ê×¼£¬¿ÉÊǸ÷×Ô±£´æÒ»¶¨µÄ¾ÖÏÞÐÔ£¬¶ÔDICÔçÆÚÕï¶Ï¼°DICÔ¤ºóÅжÏѸËٶȺÍÌØÒì¶È¾ùÓдýÌá¸ß£¬ÓÈÆäÊǶÔéæÃüµÄÅжÏÒÔ¼°pre-DICµÄÕï¶Ï£¬ÏÖÔÚÈÔȱ·¦DICÕï¶ÏµÄ½ð±ê×¼¡£Òò´ËÁÙ´²ÉÏÐèÒªÒÀÍÐеÄÄýѪ·Ö×Ó±ê¼ÇÎィÉèЧÄܸü¸ßµÄDIC¾«×¼Õï¶Ïϵͳ¡£½üÄêÑо¿Ï£Íû¿ì¡¢ÁÙ´²Ö¸µ¼ÒâÒåÇ¿µÄÐÂÐÍÄýѪ·Ö×Ó±ê¼ÇÎï°üÀ¨ÄýѪø-¿¹ÄýѪø¸´ºÏÎï(thrombin-antithrombin compex£¬TAT)¡¢ÏËÈÜø-¿¹ÏËÈÜø¸´ºÏÎï(plasmin antiplasmincomplex£¬PIC)¡¢×éÖ¯ÐÍÏËÈÜøԭ¼¤»îÎï-ÏËÈÜøԭ¼¤»îÒÖÖÆÎï-1¸´ºÏÎï(tissue plasminogen activator-plasminogen activator inhibitor-l complex£¬t-PAIC)¼°ÑªË¨µ÷ÀíÂѰ×(thrombomodulin£¬TM)¡£



03
 

ÐÂѪ˨ËÄÏîÖúÁ¦DICÔçÕïÔçÖÎ


2017Ä꣬¡¶ÖлªÑªÒºÑ§ÔÓÖ¾¡·½ÒÏþµÄ¡¶ÃÖÂþÐÔѪ¹ÜÄÚÄýѪÕï¶ÏÖйúר¼Ò¹²Ê¶¡·TAT¿ÉÓÃÓÚDICÔçÆÚÕï¶Ï¡£Í¬Ä꣬ÈÕ±¾ÑªË¨ÓëֹѪѧ»á£¨JSTH£©DICÕï¶Ï±ê×¼ÖÐÒýÈëÁËTAT¼ì²â¡£2020Ä꣬¡¶Öлª¼±ÕïҽѧÔÓÖ¾¡·½ÒÏþµÄ¡¶¼±ÐÔ³öѪÐÔÄýѪ¹¦Ð§Õϰ­ÕïÖÎר¼Ò¹²Ê¶¡·ÖÐÖ¸³ö£¬ÑªË¨·Ö×Ó±ê¼ÇÎTAT¿ÉÔçÆÚÕ¹ÍûѪ˨Ðγɺ͸´·¢Î£º¦£¬ÔçÆÚÕ¹ÍûDICΣº¦ £»PIC¿ÉÓÃÓÚDIC·ÖÐÍ¡¢ÈÜ˨ÖÎÁÆ £»tPAIC¶ÔDIC¡¢ÐÂÎÅÂöѪ˨¾ùÓÐÌáÐÑ×÷Óà £»TM¿ÉÌáÐÑѪ¹ÜÄÚÆ¤ËðÉ˿ɼûÓÚŧ¶¾Ö¢¡¢Éö¹¦Ð§ÊÜËðºÍ¼±ÐÔ·ÎËðÉ˵È¡£¹ØÓÚÁÙ´²ÇéÐÎÖØ´óµÄ»¼Õߣ¬ÍƼöʹÓÃTAT¡¢PIC¡¢tPAIC¡¢TM×÷ÔçÆÚÆÀ¹À¡£


1

TAT  ÄýѪø-¿¹ÄýѪø¸´ºÏÎï

ÌåÄÚÄýѪøÐγɺ󣬲¿·ÖѸËÙÓ뿹ÄýѪø(antithrombin£¬AT)ÍŽáÐγÉTAT£¬¸ÃÖ¸±êÊÇ·´Ó¦ÄýѪøÌìÉúµÄ·Ö×Ó±ê¼ÇÎ¿ÉѸËٵط´Ó¦ÄýѪϵͳµÄ¼¤»îˮƽ£¬Ö±½Ó·´Ó¦ÄýѪϵͳÆô¶¯¡£ÄýѪøÔÚѪҺÖаëË¥ÆÚ½öÊýÃ룬ֱ½Ó²â¶¨ÄÑÌâ¡£TATµÄѪ½¬°ëË¥ÆÚΪ3~15 min£¬¿ÉÒÔÖ±½Ó²â¶¨£¬TATѪ½¬Õý³£ÖµÎª<4 ng/mL£¬TAT>4 ng/mL£¬ÌáÐÑÄýѪøºÏ³ÉÔö¶à¡£TATÉý¸ß¿ÉÔçÆÚÕ¹ÍûѪ˨Ðγɺ͸´·¢Î£º¦¡¢ÔçÆÚÕ¹ÍûDICΣº¦¡£

2

PIC  ÏËÈÜø-¿¹ÏËÈÜø¸´ºÏÎï

PICÊÇÏËÈÜøÓëÒÖÖÆÒò×Ó¦Á2¿¹ÏËÈÜøÒÔ1:1ÍŽáÐγɵĸ´ºÏÎÊÇÖ±½Ó·´Ó¦ÏËÈÜϵͳ¼¤»îˮƽµÄÉúÎï±ê¼ÇÎï¡£PICѪ½¬°ëË¥ÆÚÔ¼6h£¬¿ÉÖ±½Ó²â¶¨£¬Ñª½¬Õý³£ÖµÎª<0.8¦Ìg/mL£¬PIC>0.8 ¦Ìg/mL³£ÌáÐÑÏËÈÜϵͳ¼¤»î¡£ÏËÈܼ¤»îˮƽÒòDIC»ù´¡¼²²¡²î±ð¶øÓÐËù²î±ð£¬ÇÒÓëDIC·ÖÐÍÇ×½üÏà¹Ø£¬¿ÉÓÃÓÚÔçÆÚÕ¹Íû¸ßÄý״̬£¬Ò²¿ÉÓÃÓÚÈÜ˨ÖÎÁƼà²â¡£

3

t-PAIC  ×éÖ¯ÐÍÏËÈÜøԭ¼¤»îÎï-ÏËÈÜøԭ¼¤»îÒÖÖÆÎï-1¸´ºÏÎï

Ѫ¹ÜÄÚÆ¤Ï¸°ûËðÉËʱ£¬×éÖ¯ÐÍÏËÈÜøԭ¼¤»îÎï¼°ÏËÈÜøԭ¼¤»îÒÖÖÆÎï-1ͬʱÊͷŵ½ÑªÒºÖУ¬1:1ÍŽáÐγÉtPAIC£¬tPAICÄܹ»·´Ó¦ÄÚÆ¤Ï¸°ûµÄËðÉË£¬ÊÇÏËÈÜϵͳ¼¤»îµÄ·Ö×Ó±ê¼ÇÎÄÐÐÔѪ½¬Õý³£Öµ<17.0 ng/mL£¬Å®ÐÔ<10.5 ng/mL¡£tPAIC ¶ÔDIC¡¢ÐÂÎÅÂöѪ˨¾ùÓÐÌáÐÑ×÷Óã¬ÊǾ²ÂöѪ˨˨ÈûÖ¢(veinthromboembolism,VTE)¼°ÐĹ£µÄΣº¦Ö¸±ê£¬±ðµÄ¸ÃÖ¸±ê¶ÔDICÕï¶Ï¾ßÓÐÖ÷Òª¼ÛÖµ£¬Ñª½¬Ë®Æ½Éý¸ßÌáÐÑDIC¿ÉÄÜѪ¹ÜÄÚÆ¤Ï¸°ûËðÉË¡¢ÑªË¨ÐγÉ¡£

4

TM  Ѫ˨µ÷ÀíÂѰ×

TMΪÄÚÆ¤Ï¸°ûÍâòµÄÄýѪøÊÜÌ壬ÒÖÖÆÄýѪøµÄ»îÐÔ£¬ÔöÇ¿ÂѰ×C»î»¯ÐÔÄÜ£¬Ñª½¬TMÕý³£ÖµÎª3.8~13.3 TU/mL¡£µ±ÄÚÆ¤Ï¸°ûÊÜËð»ò¹¦Ð§Õϰ­Ê±£¬TM±í´ï½µµÍ£¬²¿·ÖTM±»ÂѰ×øˮ½âÖÁѪ½¬ÖС£Òò´Ë£¬TMÊÇÄÚÆ¤Ï¸°ûÊÜËðµÄ±ê¼ÇÎï¡£TMÉý¸ßÌáÐÑѪ¹ÜÄÚÆ¤ËðÉË£¬¿É¼ûÓÚŧ¶¾Ö¢¡¢Éö¹¦Ð§ÊÜËð¡¢¼±ÐÔ·ÎËðÉ˵È¡£


ÐÂѪ˨ËÄÏîÍŽá¼ì²â¶ÔÕï¶ÏDICµÄ¼ÛÖµ¸ü¸ß


Ò»Ïî¶àÖÐÐÄǰհÐÔÊÓ²ìÑо¿Åú×¢TAT¡¢PIC¡¢tPAICºÍsTMÔÚ²î±ð»ù´¡¼²²¡µÄDIC»¼ÕßÖÐÌåÏÖ³öÓÅÒìµÄÕï¶ÏÐÔÄܺÍÔ¤ºó¼ÛÖµ£¬TAT¡¢tPAICºÍsTMÔÚpre-DICµÄÕï¶Ï¾ßÓÐÒ»¶¨µÄÒâÒå¡£±ðµÄ£¬ÐÂѪ˨ËÄÏîÍŽá¼ì²â¿ÉÔöÌíAUC¡¢Ñ¸ËٶȺÍÓÅÊÆ±È£¬¾ßÓиü¸ßµÄ¼ì²âЧÄÜ£¬ÓÐÖúÓÚʵʱ¸ÉÔ¤¡£



×ÛÉÏËùÊö£¬DIC»ù´¡¼²²¡¶àÑù£¬ÁÙ´²·ÖÆÚÖØ´ó£¬ÓëÆäËûѪ˨ÐÔ¼²²¡µÄÅбðÕï¶Ï½ÏÄÑÌ⣬¼«Ò×±»ºöÊÓ£¬Ê¹ÓÃͨÀýÄýѪָ±êÕï¶ÏDICʱ£¬DIC»¼ÕßÍùÍùÒѾ­½øÈëÖÐÍíÆÚ£¬´Ëʱ»¼ÕßµÄÔ¤ºóÒ»Ñùƽ³£½Ï²î£¬ÄýѪ¡¢ÏËÈÜϵͳÔÓÂÒ£¬ÄÑÒÔ»Ö¸´Õý³£Ë®Æ½£¬Ò×±¬·¢¶àÆ÷¹Ù¹¦Ð§Õϰ­×ÛºÏÕ÷£¨MODS£©£¬²¡ËÀÂʼ«¸ß¡£ÐÂѪ˨ËÄÏîTM¡¢TAT¡¢PIC¡¢t-PAICÔÚDICÔçÆÚÕï¶ÏÖоßÓÐÖ¸µ¼ÒâÒ壬²¢ÇÒ±ÈͨÀýÄýѪָ±ê¸üÔçÌáÐÑÄýѪÓëÏËÈÜϵͳÒì³££¬Åú×¢Æä¶ÔÔçÆÚDIC¾ßÓÐÓÅÒìµÄÕï¶Ï¼ÛÖµ¡£Í¨¹ýÐÂѪ˨ËÄÏî¼ì²â£¬¿ÉÖúÁ¦ÁÙ´²¾«×¼ÅжÏDICµÄʱÆÚ£¬ÌáÐÑÁÙ´²¼°Ôç¾ÙÐиÉÔ¤²¢µ÷½âÖÎÁƼƻ®¡£




6163ÒøºÓѪ˨ËÄÏî²úÆ·ÏÈÈÝ


? ÒªÁìѧ£º´Å΢Á £»¯Ñ§·¢¹â·¨

? Ñù±¾ÀàÐÍ£ºèÛéÚËáÄÆÑª½¬

? Ð£×¼ÖʿأºËæºÐÔùÓè

? ÊÊÓûúÐÍ£ºÈ«ÐÂÈý¿îÈ«×Ô¶¯»¯Ñ§·¢¹âÒÇÆ÷¡£¾ßÓÐÕ¼µØÐ¡£¬²âÊÔËÙÂʿ죬ÎÞаÐԸߵÈÓÅÊÆ£¬¿ÉÒÔÖª×ã¶àÖÖÖն˿ͻ§ÐèÇó¡£



²Î¿¼ÎÄÏ×

[1] ÖлªÒ½Ñ§»áѪҺѧ·Ö»áѪ˨ÓëֹѪѧ×飮ÃÖÉ¢ÐÔѪ¹ÜÄÚÄýѪÕï¶ÏÖйúר¼Ò¹²Ê¶(2017Äê°æ)[J]. ÖлªÑªÒºÑ§ÔÓÖ¾, 2017, 38(5):361-363.

[2] ÍõÁ¦¾ü£¬²ñÑÞ·Ò. ŧ¶¾Ö¢²¢·¢ÃÖÉ¢ÐÔѪ¹ÜÄÚÄýѪÕïÖμ±Õïר¼Ò¹²Ê¶[J].ÊÊÓÃÄ¥Á·Ò½Ê¦ÔÓÖ¾, 2017, 03(v.9):7-10.DOI:CNKI:SUN:CJCP.0.2017-03-003.

[3] ºú×ÏÞ±,ÂíÏþ´º.ÃÖÉ¢ÐÔѪ¹ÜÄÚÄýѪÕï¶Ï±ê×¼£ºÎÊÌâÓëÆÚÍû[J].ÖйúÊÊÓÃÄÚ¿ÆÔÓÖ¾,2021,41(06):457-461.DOI:10.19538/j.nk2021060101.

[4] Ëξ°´º,ÕÅΰ,ÕÅÀÚ,µÈ.ÖØÖ¢»¼ÕßÄýѪ¹¦Ð§Õϰ­±ê×¼»¯ÆÀ¹ÀÖйúר¼Ò¹²Ê¶[J].½â·Å¾üҽѧÔÓÖ¾,2022,47(02):107-117.

[5] ÉÛÃã,ѦÏÔ×Å,Íõ˼¼Ñ,µÈ.¼±ÐÔ³öѪÐÔÄýѪ¹¦Ð§Õϰ­ÕïÖÎר¼Ò¹²Ê¶[J].Öлª¼±ÕïҽѧÔÓ,2020,29(6):780-787.

[6] Wada H, Takahashi H, Uchiyama T, et al. The approval of revised diagnostic criteria for DIC from the Japanese Society on Thrombosis and Hemostasis[J]. Thrombosis Journal, 2017,15(1).

[7] Mei H, Jiang Y, Luo L, et al. Evaluation the combined diagnostic value of TAT, PIC, tPAIC, and sTM in disseminated intravascular coagulation: A multi-center prospective observational study. Thromb Res. 2019;173:20-26.


END

ÎÄÕÂȪԴ£º6163ÒøºÓÉúÎï

Ôð±à£ºEcho

У¶Ô£ºPretty¡¢Miss Jia


 
ÍøÕ¾µØÍ¼